InvestorsHub Logo
Followers 13
Posts 1320
Boards Moderated 0
Alias Born 12/30/2016

Re: None

Wednesday, 09/06/2017 10:20:41 AM

Wednesday, September 06, 2017 10:20:41 AM

Post# of 789
Verastem upgraded to Overweight after duvelisib data at Cantor


As previously reported, Cantor Fitzgerald analyst Mara Goldstein upgraded Verastem to Overweight from Neutral after the company reported Phase 3 DUO study data on duvelisib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma that was "squarely positive" and suggests a viable commercial opportunity. The analyst, who predicts that duvelisib can capture a reasonable market share in both high risk and low/medium risk patients with relapsed/refractory CLL, raised her price target on Verastem shares to $17 from $2.

Read more at:
https://thefly.com/landingPageNews.php?id=2605312

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VSTM News